Abstract:Editorial for “T1 Mapping on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Oxaliplatin-Induced Liver Injury in a Mouse Model” Oxaliplatin (OXA) is a third-generation platinum commonly used antitumor drug and is used in the treatment of gastrointestinal cancers. The most common use is seen in colorectal cancers followed by the gastric, liver, and pancreatic cancers. OXA is a cisplatin derivative and has less renal toxicity compared with cisplatin. However, there are many studies showing significant damage to nontumor-bearing liver. This damage evaluation is now being done by a T1 mapping of the gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) contrast study by magnetic resonance imaging (MRI). This is a newer, novel concept for risk assessment and injury evaluation being done in a mouse model. The results show significant potential for liver injury evaluation. OXA is more a commonly used antitumor drug for various cancers in mouse models. This chemotherapeutic agent has involved many studies for various grades of the hepatic injury in the normal liver. The most common presentation is so-called sinusoidal obstruction syndrome (SOS). SOS is significantly characterized by obliteration and dilatation of the liver sinusoids due to collagenization of the perisinusoidal space. This is due to erythrocyte extravasation and hepatocyte plate disruption. These changes can cause inhibition of future remnant liver hypertrophy following portal vein embolization, increased risk of intraoperative bleeding and transfusion rate, intrahepatic sinus platelet aggregation, hepatocyte atrophy and necrosis, hepatic steatosis, steatohepatitis, intrahepatic sinus haemorrhage, and sinusoidal obstruction syndrome hepatomegaly with pain, splenomegaly, ascites, hepatic vein narrowing (HVN), and gall bladder wall thickening and an increased rate of liver insufficiency and ultimately may lead to hepatectomy. In the early form this can be misinterpreted as metastases. Thus, early diagnosis of SOS by imaging is important for the management of patients prior to surgery and during follow-up. These changes are difficult to evaluate by routine imaging. Gd-EOB-DTPA is a commonly used MR contrast agent for T1weighted images. 6 After intravenous injection, Gd-EOB-DTPA is cleared by biliary excretion and renal excretion. Gd-EOB DTPA is taken up by hepatocytes and excreted via the biliary pathway. In this issue, Yang et al, report that GdEOB-DTPA has a T1-shortening effect, so the measurement of the T1 relaxation time of liver parenchyma before and after GdEOB-DTPA administration allows quantitative evaluation of Gd-EOB-DTPA uptake by the liver parenchyma, thus reflecting liver function. Thus, with this same concept, it was described in a mouse model of the efficacy of this contrast agent. Organic anion-transporting polypeptide (OATP) is known to mediate the uptake of Gd-EOB-DTPA by hepatocytes and multidrug resistance protein (MRP), which further mediates biliary excretion of Gd-EOBDTPA. Reduced reduction rates of T1 relaxation time in liver fibrosis may be explained by a hypofunction of OATP and fewer normalfunctioning hepatocytes. After Gd-EOB-DTPA injection, the beginning of the hepatocyte uptake could be identified at 1.5 minutes and 50% of the administered dose was transported into the hepatocytes at 20 minutes. Therefore, the imaging at 20 minutes after Gd-EOB-DTPA injection was used as a “standard” hepatobiliary phase (HBP) to assess liver lesions and function. The HBP imaging obtained at 10 minutes is a feasible timepoint for replacing 20-minute HBP imaging after Gd-EOB-DTPA injection to diagnose liver lesion with a 3.0T MRI system. The reason here is that the MRI signal-to-noise ratio (SNR) can be expected to increase by twofold at 3.0T than 1.5T, and the contrast-to noise ratio (CNR) also would be improved. The mouse model study shows liver function and injury after OXA therapy. This shows the significant importance of the T1 mapping in the successful evaluation of liver injury. This again will be able to differentiate from metastases, also especially in the early stages.

Validation of Imaging Biomarkers of Steatosis in ob / ob Mice with Multiple SPIO Injections

T1rho Shortening Effect of Fat in Liver Steatosis after Fat Suppression: Approximate Estimation in a Methionine and Choline-Deficient (MCD) Diet Rat Model.

Free-breathing liver fat quantification using a multiecho 3D stack-of-radial technique.

Quantitative Activity Measurements of Brown Adipose Tissue at 7 T Magnetic Resonance Imaging After Application of Triglyceride-Rich Lipoprotein 59Fe-Superparamagnetic Iron Oxide Nanoparticle: Intravenous Versus Intraperitoneal Approach

Comparative analysis of hepatic fat quantification across 5 T, 3 T and 1.5 T: A study on consistency and feasibility

Measuring liver triglyceride content in mice: non-invasive magnetic resonance methods as an alternative to histopathology

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

[Measurement of Intrahepatic Triglyceride Stores by 1H Magnetic Resonance Spectroscopy: Study with Rat Models and in Patients].

SPIO-labeled Yttrium Microspheres for MR Imaging Quantification of Transcatheter Intrahepatic Delivery in a Rodent Model.

MRI Dixon Fat-Corrected Look-Locker T1 Mapping for Quantification of Liver Fibrosis and Inflammation—A Comparison With the Non–Fat-Corrected Shortened Modified Look-Locker Inversion Recovery Technique

Multiparametric ultrasound imaging for early‐stage steatosis: Comparison with magnetic resonance imaging‐based proton density fat fraction

Longitudinal evaluation of hepatic lipid deposition and composition in ob/ob and ob/+ control mice

Validation of Goose Liver Fat Measurement by QCT and CSE-MRI with Biochemical Extraction and Pathology As Reference.

Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic resonance imaging in patients with obesity: a secondary cross-sectional study

Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance

R2* Impact on Hepatic Fat Quantification With a Commercial Single Voxel Technique at 1.5 and 3.0 T

Simultaneous liver steatosis, fibrosis and iron deposition quantification with mDixon quant based on radiomics analysis in a rabbit model

R1ρ at High Spin-Lock Frequency Could Be a Complementary Imaging Biomarker for Liver Iron Overload Quantification.

Editorial for “T1 Mapping on Gd‐EOB‐DTPA‐Enhanced MRI for the Prediction of Oxaliplatin‐Induced Liver Injury in a Mouse Model”

Validation study of perfusion parameter in hypervascular hepatocellular carcinoma and focal nodular hyperplasia using dynamic susceptibility magnetic resonance imaging with super-paramagnetic iron oxide: comparison with single level dynamic CT arteriography

Gadoxetic acid-enhanced magnetic resonance imaging in the assessment of hepatic sinusoidal obstruction syndrome in a mouse model